No black box warning on record for Byooviz

As of the latest FDA labeling reviewed, Byooviz (RANIBIZUMAB-NUNA) does not carry a black box warning. Standard warnings and precautions still apply — see the full Byooviz medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Endophthalmitis and retinal detachments may occur following intravitreal injections. Patients should be monitored following the injection ( 5.1 ). Increases in intraocular pressure (IOP) have been noted both pre- and post-intravitreal injection ( 5.2 ). There is a potential risk of arterial thromboembolic events following intravitreal use of VEGF inhibitors ( 5.3 ). 5.1

No black box warning on record for Byooviz

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Endophthalmitis and retinal detachments may occur following intravitreal injections. Patients should be monitored following the injection ( 5.1 ). Increases in intraocular pressure (IOP) have been noted both pre- and post-intravitreal injection ( 5.2 ). There is a potential risk of arterial thromboembolic events following intravitreal use of VEGF inhibitors ( 5.3 ). 5.1

Byooviz Black Box Warning

No black box warning on record for Byooviz

Other warnings & precautions

Byooviz Black Box Warning

No black box warning on record for Byooviz

Other warnings & precautions